aTyr reports Q3 2026 results, gains FDA alignment on sarcoidosis Phase 3 protocol
aTyr will seek partners to fund the Phase 3 study after aligning with FDA on using FVC as the primary endpoint, while reporting $50.3 million in cash.
aTyr Pharma said it reached alignment with FDA on a proposed Phase 3 study of efzofitimod in pulmonary sarcoidosis with restrictive lung disease, using FVC as the primary endpoint, with study-related activities already underway.1 The company said it plans to focus on securing strategic partnerships to help advance the Phase 3 study.1
More specifically, aTyr said it has begun early work on the trial but is looking to strategic partnerships or licensing deals to fund the Phase 3 program once the initial study-related activities are complete.1
On the pipeline side, aTyr said it completed enrollment in the Phase 2 "EFZO-CONNECT" study of efzofitimod in patients with limited or diffuse systemic sclerosis-related interstitial lung disease.1 Full results from that study are expected in the second quarter of 2027.1 The company said the data set will cover several endpoints such as skin scoring, skin tissue analysis, gene activity patterns, immune markers, lung function measured by forced vital capacity, and an analysis of dose-response relationships.1
aTyr also noted that results from its completed Phase 3 "EFZO-FIT" study in pulmonary sarcoidosis were published in The Lancet Respiratory Medicine.1
On earlier-stage work, the company said it entered into a research partnership with Montefiore Einstein to study ATYR2810, an antibody aimed at the NRP2 receptor, as a potential treatment approach for pediatric osteosarcoma.1
Turning to finances, aTyr reported $50.3 million in cash, cash equivalents, restricted cash, and available-for-sale investments as of September 30, 2026, which it said should fund operations into late 2028 based on its current plans.1 Research and development expenses were $10.4 million and general and administrative expenses were $8.3 million for the quarter ended September 30, 2026. Research and development expenses were $10.4 million for the third quarter 2026, driven mainly by the Phase 2 EFZO-CONNECT study and preclinical work, while general and administrative expenses were $8.3 million for the quarter.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.